Longevity & AgingGLP-1 Drugs Reshape Obesity Treatment as Surgery Declines and New Data Emerges
A wave of new research is reshaping how obesity, menopause, and metabolic health are managed. GLP-1 medications like semaglutide and tirzepatide are now dramatically outpacing bariatric surgery in usage, with clinical trials confirming strong weight maintenance on continued dosing. Global obesity trends are finally slowing in wealthy nations. For women, perimenopause emerges as a critical window for cardiovascular and bone health, with osteoporosis linked to a 47% higher risk of death in postmenopausal women. Creatine supplementation is gaining attention as a tool to preserve muscle mass during menopause. Novel oral GLP-1 agents and triple agonists are showing impressive early results, pointing toward a rapidly expanding treatment landscape for metabolic disease.
